Research article · 11 Jan 2023
Research articlePublished 2015
Evaluation of a Retrospective Drug Utilization Review Program for the Treatment of Plaque Psoriasis: A Pilot Study
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Because of their increasing use and high unit costs, biologics pose challenges to payer costcontainment efforts. Creative approaches are needed to assure clinical appropriateness and eliminate unnecessary costs related to biological medications. The biologic etanercept has been approved for treatment of chronic moderate to severe plaque psoriasis in certain adults; however the costs can be over $2,000 per month. Objective: The objective of this study was to evaluate the outcomes of a specialty pharmacy’s retrospective drug utilization review (rDUR) pilot program designed to identify patients with plaque psoriasis who were prescribed a dose of etanercept inconsistent with the manufacturer recommended dosing for plaque psoriasis. Methods: This descriptive analysis evaluated a pharmacist-initiated, provider-oriented rDUR pilot program for plaque psoriasis patients using etanercept. We assessed the rDUR program’s impact on annual cost. A retrospective descriptive analysis was undertaken to assess the rDUR program’s impact on annual cost associated with changes in dosage in prescribed amounts of etanercept for patients with plaque psoriasis. We examined prescription “fills” and cost per patient pre- and post-program implementation using wholesale acquisition costs (WAC). Retrospective DUR review criteria were based on dosing information contained in the prescribing label. Results: The rDUR targeted 388 providers with 444 plaque psoriasis patients; prescriber response rate to faxed reminder letters was 65.5%. Annual costs for etanercept patients had an upper range of $37,638, and annual payer savings associated with reduced dosing regimens were projected to be an average of $22,062 per patient per year. Conclusion: Proactive therapy management approaches are necessary for specialty medications to help eliminate unnecessary health-care expenses related to unintended prescribing in excess of the manufacturer’s recommended dosing. Pharmacist-led programs to provide information regarding manufacturer dosing recommendations can effectively be incorporated into specialty pharmacy, and can significantly and positively influence prescribing and control costs.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Review article · 2014
Biologicals in the Treatment of Plaque Psoriasis: Drug Selection by Means of the SOJA Method
Review article · 24 May 2018
EVALUATION OF METHOTREXATE EFFICIENCY IN COMPARISON TO ALTERNATIVE DRUGS FOR THE TREATMENT OF PSORIASIS IN THE UK ADULT POPULATION: A SYSTEMATIC REVIEW
Short communication · 30 Sep 2023
Pharmacokinetics in Pediatric Patients With Moderate to Severe Plaque Psoriasis: Implications for Treatment
Commentary · 29 Nov 2023
Behind the Scenes of Healthcare: Unraveling the Impact of Drug Utilization Review Programs
More from this journal
The newest in Journal of Pharmaceutical Care & Health Systems.
Review article · 9 Jun 2025
Blood Fluid: The Unseen Currents That Bind Life and Death Together
Research article · 8 Jun 2025
Formulation and Antibacterial Evaluation of Acmella olaracea (Akarkara) Gummies Used for Toothache
Research article · 9 Apr 2025
Deep Vein Thrombosis: A Closer Look at a Silent Threat
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmaceutical Care & Health Systems
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Bobby L Clark”
- BylineArticles whose byline prints “Janeen DuChane”
- BylineArticles whose byline prints “Francis Staskon”
- BylineArticles whose byline prints “Mike Einodshofer”
- BylineArticles whose byline prints “Karen Fitzner”
- BylineArticles whose byline prints “Ian Duncan”

